Therapeutic potential of CKD-506, a novel selective histone deacetylase 6 inhibitor, in a murine model of rheumatoid arthritis.

Jin Kyun ParkYu Jin JangBo Ram OhJieun ShinDaekwon BaeNina HaYoung Il ChoiGi Soo YounJinseu ParkEun Young LeeEun Bong LeeYeong-Wook Song

Published in: Arthritis research & therapy (2020)

The novel HDAC6 inhibitor CKD-506 suppresses inflammatory responses by monocytes/macrophages, improves Treg function, and ameliorates arthritis severity in a murine model of RA. Thus, CKD-506 might be a novel and effective treatment option for RA.

Keyphrases

rheumatoid arthritis
histone deacetylase
chronic kidney disease
disease activity
ankylosing spondylitis
interstitial lung disease
signaling pathway
dendritic cells
mouse model
systemic lupus erythematosus
peripheral blood
combination therapy